{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:31:54Z","timestamp":1787232714086,"version":"build-2736575974"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Reactivation of cytomegalovirus (CMV) and Epstein\u2013Barr virus (EBV) is a major complication in immunocompromised patients, and understanding donor variability in antiviral immunity is essential for optimizing adoptive T-cell therapy. This study aimed to identify immunogenetic determinants of virus-specific T-cell responses in healthy donors to guide donor selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CMV- and EBV-specific T-cell responses were characterized using flow cytometry and IFN-g ELISpot after stimulation with peptide pools, followed by integrated analyses correlating the response magnitude with human leukocyte antigen (HLA) class I and II alleles, HLA haplotypes, and HLA-G 3\u2032UTR polymorphisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CMV 65-kDa phosphoprotein (pp65) induced stronger CD8\n                      <jats:sup>+<\/jats:sup>\n                      and CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell responses than immediate early 1 (IE1), whereas the EBV consensus peptides preferentially activated CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Several HLA alleles and linked haplotypic backgrounds were associated with enhanced or reduced CMV-specific T-cell responses, including an A*01:01~C*07:01~B*08:01~DRB1*03:01~DQB1*02:01 haplotype enriched among low responders. For EBV, several HLA-restricted alleles were associated with stronger peptide-specific activation, supporting the broad immunogenicity of the consensus peptide pool. Moreover, HLA-G 3\u2032UTR polymorphisms selectively modulated the CMV-specific IFN-\u03b3\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell frequencies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Together, these results indicate that classical and non-classical HLA variations are associated with inter-donor differences in antiviral T-cell response in an antigen- and virus-dependent manner, providing a translational framework to refine donor selection and improve the design of T-cell-based immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1856550","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:32:25Z","timestamp":1786685545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Human leukocyte antigen genotype modulates cytomegalovirus- and Epstein\u2013Barr virus-specific T-cell response in healthy donors for optimized virus-specific T-cell donor selection"],"prefix":"10.3389","volume":"17","author":[{"given":"Rut","family":"Mora-Buch","sequence":"first","affiliation":[{"name":"Advanced & Cell Therapy Services, Blood and Tissue Bank (BST)","place":["Barcelona, Spain"]},{"name":"Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat Aut\u00f2noma de Barcelona (VHIR-UAB)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Pasamar","sequence":"additional","affiliation":[{"name":"Advanced & Cell Therapy Services, Blood and Tissue Bank (BST)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tom\u00e1s-Mar\u00edn","sequence":"additional","affiliation":[{"name":"Advanced & Cell Therapy Services, Blood and Tissue Bank (BST)","place":["Barcelona, Spain"]},{"name":"Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat Aut\u00f2noma de Barcelona (VHIR-UAB)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Enrich","sequence":"additional","affiliation":[{"name":"Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat Aut\u00f2noma de Barcelona (VHIR-UAB)","place":["Barcelona, Spain"]},{"name":"Immunogenetics and Histocompatibility Laboratory, Blood and Tissue Bank (BST)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Andr\u00e9s-Rozas","sequence":"additional","affiliation":[{"name":"Advanced & Cell Therapy Services, Blood and Tissue Bank (BST)","place":["Barcelona, Spain"]},{"name":"Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat Aut\u00f2noma de Barcelona (VHIR-UAB)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleof\u00e9","family":"Pe\u00f1a-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Barcelona Supercomputing Center","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Garc\u00eda Bosca","sequence":"additional","affiliation":[{"name":"Advanced & Cell Therapy Services, Blood and Tissue Bank (BST)","place":["Barcelona, Spain"]},{"name":"Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat Aut\u00f2noma de Barcelona (VHIR-UAB)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Rudilla","sequence":"additional","affiliation":[{"name":"Transfusional Medicine Group, Vall d'Hebron Research Institute, Universitat Aut\u00f2noma de Barcelona (VHIR-UAB)","place":["Barcelona, Spain"]},{"name":"Immunogenetics and Histocompatibility Laboratory, Blood and Tissue Bank (BST)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jaci.2015.12.1311","article-title":"Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes","volume":"137","author":"Naik","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10339","DOI":"10.1038\/s41467-024-54595-2","article-title":"Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years","volume":"15","author":"Neller","year":"2024","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/jci165476","article-title":"Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant","volume":"15","author":"Prockop","year":"2023","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007103","article-title":"Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant","volume":"6","author":"Jiang","year":"2022","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.05.019","article-title":"Virus-specific T cell therapy to treat refractory viral infections in solid organ transplant recipients","volume":"24","author":"Schweitzer","year":"2024","journal-title":"Am J Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.07.015","article-title":"CMV-, EBV- and ADV-specific T cell immunity: Screening and monitoring of potential third-party donors to improve post-transplantation outcome","volume":"19","author":"Sukdolak","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/tan.15419","article-title":"Development and characterization of a cell donor registry for virus-specific T cell manufacture in a blood bank","volume":"103","author":"Rudilla","year":"2024","journal-title":"HLA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01591","article-title":"Comprehensive analysis of cytomegalovirus pp65 antigen-specific CD8+ T cell responses according to human leukocyte antigen class I allotypes and intraindividual dominance","volume":"8","author":"Hyun","year":"2017","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.602014","article-title":"Comprehensive analysis of CD4+ T cell responses to CMV pp65 antigen restricted by single HLA-DR, -DQ, and -DP allotype within an individual","volume":"11","author":"Hyun","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007005","article-title":"Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy","volume":"6","author":"Hasan","year":"2022","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"572.e1","DOI":"10.1016\/j.jtct.2023.06.001","article-title":"Virus-specific T cells from cryopreserved blood during an emergent virus outbreak for a potential off-the-shelf therapy","volume":"29","author":"Mora-Buch","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10875-025-01901-2","article-title":"BK virus-specific T cell response associated with HLA genotypes, RhD status, and CMV or EBV serostatus in healthy donors for optimized cell therapy","volume":"45","author":"Mora-Buch","year":"2025","journal-title":"J ClinImmunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/tan.12356","article-title":"The HLA-net GENE[RATE] pipeline for effective HLA data analysis and its application to 145 population samples from Europe and neighbouring areas","volume":"83","author":"Nunes","year":"2014","journal-title":"Tissue Antigens"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/tan.13644","article-title":"HLA-A, -B, -C, -DRB1, and -DQB1 allele and haplotype frequencies: An analysis of umbilical cord blood units at the Barcelona Cord Blood Bank","volume":"94","author":"Enrich","year":"2019","journal-title":"HLA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.10.5512","article-title":"Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus1","volume":"163","author":"Solache","year":"1999","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.727814","article-title":"Adoptive cell transfer of allogeneic Epstein-Barr virus-specific T lymphocytes for treatment of refractory EBV-associated posttransplant smooth muscle tumors: A case report","volume":"12","author":"Hansen","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"18646","DOI":"10.1038\/s41598-020-75639-9","article-title":"Variability at the 3\u2032 untranslated region of the HLA-G gene: a study on patients with AIDS and cytomegalovirus retinochoroiditis","volume":"10","author":"Vicente","year":"2020","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112338","article-title":"Recipient HLA-G +3142 CC genotype and concentrations of soluble HLA-G impact on occurrence of CMV infection after living-donor kidney transplantation","volume":"18","author":"Guberina","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01178","article-title":"HLA-G genotype\/expression\/disease association studies: Success, hurdles, and perspectives","volume":"11","author":"Amodio","year":"2020","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/immu.200390015","article-title":"Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation","volume":"33","author":"Contini","year":"2003","journal-title":"Eur J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.12.6100","article-title":"Cutting edge: soluble HLA-G1 triggers CD95\/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8","volume":"164","author":"Fournel","year":"2000","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1627824","article-title":"Cytomegalovirus and Epstein-Barr infections: Prevalence and impact on patients with hematological diseases","volume":"2020","author":"de Melo Silva","year":"2020","journal-title":"BioMed Res Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1038\/s41467-024-47057-2","article-title":"Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment","volume":"15","author":"Keller","year":"2024","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/v15071510","article-title":"Virus-specific T-cell therapy for viral infections of the central nervous system: a review","volume":"15","author":"Lambert","year":"2023","journal-title":"Viruses"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01272","article-title":"Virus-specific T cells for the immunocompromised patient","volume":"8","author":"Houghtelin","year":"2017","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000540961","article-title":"Virus-specific T-cell therapy for the management of viral infections in the immunocompromised","volume":"52","author":"Koukoulias","year":"2025","journal-title":"Transfus Med Hemotherapy Off Organ der Dtsch Gesellschaft fur Transfusionsmedizin und Immunhamatologie"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.07.014","article-title":"Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation","volume":"14","author":"Bao","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.82050","article-title":"SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells","volume":"11","author":"Pothast","year":"2022","journal-title":"Elife"},{"key":"B30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.immuni.2013.08.034","article-title":"Antigen availability determines CD8+ T cell-dendritic cell interaction kinetics and memory fate decisions","volume":"39","author":"Henrickson","year":"2013","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02425-12","article-title":"Intensity of the humoral response to cytomegalovirus is associated with the phenotypic and functional status of the immune system","volume":"87","author":"R.","year":"2013","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414830","article-title":"Cellular immunity against cytomegalovirus and risk of infection after kidney transplantation","author":"Blom","year":"2024","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/jci121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000371","article-title":"Mini\u201d bank of only 8 donors supplies CMV-directed T cells to diverse recipients","volume":"3","author":"Tzannou","year":"2019","journal-title":"Blood Adv"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016202","article-title":"Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies","volume":"141","author":"Quach","year":"2023","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.11.7569-7579.1996","article-title":"The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL","volume":"70","author":"Wills","year":"1996","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-72","article-title":"Identification of HLA-A*2402-restricted HCMV immediate early-1 (IE-1) epitopes as targets for CD8+ HCMV-specific cytotoxic T lymphocytes","volume":"7","author":"Lim","year":"2009","journal-title":"J Transl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15753.1","article-title":"Cytomegalovirus infection and progressive differentiation of effector-memory T cells","volume":"7","author":"Pardieck","year":"2018","journal-title":"F1000Research"},{"key":"B41","doi-asserted-by":"publisher","first-page":"110071","DOI":"10.2139\/ssrn.3881346","article-title":"Heterogeneity of human anti-viral immunity shaped by virus, tissue, age, and sex","volume":"37","author":"Poon","year":"2021","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(03)00028-4","article-title":"Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles","volume":"64","author":"Lacey","year":"2003","journal-title":"Hum Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07969.x","article-title":"Cytomegalovirus-specific CD8(+) T cells targeting different HLA\/peptide combinations correlate with protection but at different threshold frequencies","volume":"148","author":"Giest","year":"2010","journal-title":"Br J Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/jci163548","article-title":"Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors","volume":"133","author":"Bonifacius","year":"2023","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1412211","article-title":"EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation","volume":"15","author":"Cooper","year":"2024","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737365","article-title":"Extensive HLA class I allele promiscuity among viral CTL epitopes","volume":"37","author":"Frahm","year":"2007","journal-title":"Eur J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.826074","article-title":"Role of HLA-G in viral infections","volume":"13","author":"Jasinski-Bergner","year":"2022","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00251-003-0547-z","article-title":"HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels","volume":"55","author":"Hviid","year":"2003","journal-title":"Immunogenetics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2018.08.003","article-title":"Genetic association between HLA-G 14-bp polymorphism and diseases: A systematic review and meta-analysis","volume":"79","author":"de Almeida","year":"2018","journal-title":"Hum Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031799","article-title":"Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells","volume":"199","author":"Wolint","year":"2004","journal-title":"J Exp Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2009.74","article-title":"The genetic structure of 3\u2019untranslated region of the HLA-G gene: polymorphisms and haplotypes","volume":"11","author":"Castelli","year":"2010","journal-title":"Genes Immun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"23070","DOI":"10.1038\/s41598-021-02106-4","article-title":"HLA-G genetic diversity and evolutive aspects in worldwide populations","volume":"11","author":"Castelli","year":"2021","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.04.007","article-title":"High-resolution HLA allele and haplotype frequencies in several unrelated populations determined by next generation sequencing: 17th International HLA and Immunogenetics Workshop joint report","volume":"82","author":"Creary","year":"2021","journal-title":"Hum Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017097","article-title":"Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction","volume":"9","author":"Rubinstein","year":"2025","journal-title":"Blood Adv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1856550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:19:02Z","timestamp":1787231942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1856550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2026.1856550"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1856550","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1856550"}}